Table 1.

The approved immune checkpoint inhibitors in the globe

Target	Active Ingredients	First approval time	Company	Application(approved in the globe)
PD-1	Nivolumab	2014	Bristol Myers Squibb	Melanoma, NSCLC, MPM, RCC, HL HNSCC, UC, CRC, HCC, Esophageal Cancer, GC, GEJC, EA
	Pembrolizumab	2014	Merck Sharp Dohme	Melanoma, NSCLC, HNSCC, HL, PMBCL, UC, CRC, GC, Esophageal cancer, CC, HCC, MCC, RCC, Endometrial carcinoma, CSCC, TNBC
	Cemiplimab	2018	Regeneron Pharmaceuticals	CSCC, BCC, NSCLC
	Toripalimab	2018	Shanghai Junshi Biosciences Co., Ltd.	Melanoma, UC, NPC, ESCC
	Sintilimab	2018	Innovent Biologics, Inc	NSCLC, HL, HCC, ESCC, GC, GEJC
	Camrelizumab	2019	Jiangsu Hengrui Medicine Co.,Ltd.	NSCLC, HL, HCC, ESCC, NPC
	Tislelizumab	2019	Beigene, Ltd.	NSCLC, HL, UC, HCC, NPC, ESCC, CRC
	Zimberelimab	2021	Guangzhou Gloria Biosciences Co., Ltd.	HL
	Prolgolimab	2020	Biocad.	Melanoma, SC
	Dostarlimab	2021	GSK Plc	Endometrial carcinoma
PD-L1	Atezolizumab	2016	Genetech Inc	Melanoma, NSCLC, SCLC, HCC, ASPS
	Durvalumab	2017	AstraZeneca	NSCLC, ES-SCLC, BTC, HCC
	Avelumab	2017	EMD Serono Inc	UC, MCC, RCC
CTLA-4	Ipilimumab	2011	Bristol Myers Squibb	Melanoma, RCC, CRC, HCC, NSCLC, MPM, Esophageal cancer

Abbreviations: ASPS Alveolar soft part sarcoma, BCC Basal cell carcinoma, BTC Biliary tract cancer, CC Cervical cancer, CRC Colorectal cancer, CSCC Cutaneous squamous cell carcinoma, EA Esophageal adenocarcinoma, ESCC Esophageal squamous cell carcinoma, ES-SCLC Extensive-stage small cell lung cancer, GC Gastric cancer, GEJC Gastroesophageal junction cancer, HCC Hepatocellular carcinoma, HL Hodgkin lymphoma, HNSCC Head and neck squamous cell cancer, MCC Merkel cell carcinoma, MPM Malignant pleural mesothelioma, NPC Nasopharyngeal carcinoma, NSCLC Non-small cell lung cancer, PMBL Primary mediastinal B cell lymphoma, RCC Renal cell carcinoma, SC Skin cancer, SCLC Small cell lung cancer, TNBC Triple-negative breast cancer, UC Urothelial carcinoma